Bausch + Lomb Initiates First Clinical Trial for Technolas Teneo Excimer Laser in the United States
July 31, 2019
July 31, 2019
BRIDGEWATER, New Jersey, July 31 -- Bausch + Lomb issued the following news release:
Bausch + Lomb, a leading global eye health company, today announced that it has initiated the first in a series of U.S. clinical trials to evaluate the safety and efficacy of the Technolas(R) Teneo(TM) excimer laser for vision correction surgery for myopia and myopic astigmatism.
"This is an exciting milestone for our organization, as it's the first step on the road to filing . . .
Bausch + Lomb, a leading global eye health company, today announced that it has initiated the first in a series of U.S. clinical trials to evaluate the safety and efficacy of the Technolas(R) Teneo(TM) excimer laser for vision correction surgery for myopia and myopic astigmatism.
"This is an exciting milestone for our organization, as it's the first step on the road to filing . . .